Integrated Assay Platform Targeting HMPV Infection
Human metapneumovirus (HMPV) is a common cause of respiratory tract infections in young children, older adults, and people with weakened immune systems. HMPV is in the Pneumoviridae family along with the more commonly known respiratory syncytial virus (RSV). Currently, there is no specific antiviral therapy to treat HMPV and no vaccine to prevent HMPV.
At the ICAR2024 Conference, WuXi AppTec presented a poster showcasing our integrated assay platform to support research in this area. The authors demonstrate the effectiveness of this platform by evaluating potential HMPV inhibitors in a mouse HMPV infection model, HMPV cell-based infection and neutralization assays, and replicon and cell fusion reporter assays.
Poster_ICAR2024_HMPV Antiviral Platform
Related Content
Viruses have well-established causal roles in numerous human cancers. Approximately 10% of cancers globally are attributed to viral infections, primarily...
VIEW RESOURCESARS-CoV-2 antivirals which have been clinically approved or are in late-stage development are directed against either the RNA-dependent RNA polymerase...
VIEW RESOURCE